Abstract Search

ea0073aep95 | Calcium and Bone | ECE2021

High dose short term glucocorticoid (gc) treatment seems to have no long term negative effect on bone mineral density (bmd) of newly diagnosed multiple sclerosis (ms) patients

Simeakis George , Saltiki Katerina , Fakas Nikolaos , Koutsikos John , Athanasiou Kostas , Papatheodorou George , Papatheodorou Athanasios , Zapanti Evangelia , Anagnostouli Maria , Alevizaki Maria , Terpos Evangelos

ObjectivesHigh-Dose-Intravenous-Steroid-Treatment-(HDIST) represents the first choice of treatment for MS relapses. Although chronic oral GC-administration is associated with bone loss there are still conflicting data regarding HDIST. Methods25 newly-diagnosed MS-patients (10-women) were prospectively enrolled meeting the following eligibility criteria: age 1845 yrs, fully ambulatory, women with normal ...

0 shares

ea0099p163 | Thyroid | ECE2024

The effect of monoclonal antibodies alemtuzumab and ocrelizumab on the thyroid function of patients with multiple sclerosis

Kazakou Paraskevi , G Vakrakou Aigli , Tzanetakos Dimitrios , S Tzartos John , Anagnostouli Maria , Stathopoulos Panos , Dermentzoglou Alexandros , N Kassi Georgia , Kilidireas Constantinos , Zapanti Evangelia

Aim: Autoimmune thyroid disease (AITD) is the most common adverse effect in alemtuzumab (ALZ) treated relapsingremitting (RR) multiple sclerosis (MS) patients. The objective of this prospective study was to analyze the occurrence, timing of onset, clinical course, and laboratory characteristics of AITD post-ALZ and subsequently the clinical outcome of AITD post-ALZ in patients who received ocrelizumab.Patients and methods: We evaluated 36 RRMS pati...

0 shares

Endocrine Abstracts

High dose short term glucocorticoid (gc) treatment seems to have no long term negative effect on bone mineral density (bmd) of newly diagnosed multiple sclerosis (ms) patients

The effect of monoclonal antibodies alemtuzumab and ocrelizumab on the thyroid function of patients with multiple sclerosis

BiosciAbstracts